CELERNA

Welcome to the Brand page for “CELERNA”, which is offered here for Research and development in the fields of pharmaceuticals, therapeutics, and biologics, exosome-based delivery systems for pharmaceuticals, therapeutics, and biologics; medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; research and development of delivery systems for therapeutic compounds, exosome-based drug delivery systems for therapeutic compounds for the treatment of viral pathogens, cancer and inherited disorder in humans; research and development of delivery systems for therapeutic compounds, exosome-based drug delivery of therapeutic compounds; research and development of delivery systems for therapeutic nucleic acids, exosome-based drug delivery of therapeutic nucleic acids, rna; research and development of delivery systems for therapeutic peptides, exosome-based drug delivery of therapeutic peptides; research and development of delivery systems for gene-editing proteins, exosome-based drug delivery of gene-editing proteins; research and development of delivery systems for vaccines, exosome-based drug delivery systems for vaccines; research and development of the production of exosomes for therapeutic uses, yeast-based exosome for therapeutic uses; research and development of new biological products for therapeutic use; design and development of nucleic acids, proteins, enzymes, and drug compounds for use in pharmaceuticals, biotechnology, medical, and diagnostic applications;.

Its status is currently believed to be active. Its class is unavailable. “CELERNA” is believed to be currently owned by “Spartina Biotechnologies, Inc.”